vs
Side-by-side financial comparison of Local Bounti Corporation (LOCL) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
Intellia Therapeutics, Inc. is the larger business by last-quarter revenue ($23.0M vs $12.5M, roughly 1.8× Local Bounti Corporation). Local Bounti Corporation runs the higher net margin — -69.8% vs -416.2%, a 346.3% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 23.7%). Local Bounti Corporation produced more free cash flow last quarter ($-3.6M vs $-69.4M). Over the past eight quarters, Local Bounti Corporation's revenue compounded faster (21.9% CAGR vs -10.8%).
Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
LOCL vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $23.0M |
| Net Profit | $-8.7M | $-95.8M |
| Gross Margin | 12.2% | — |
| Operating Margin | -106.1% | -428.9% |
| Net Margin | -69.8% | -416.2% |
| Revenue YoY | 23.7% | 78.8% |
| Net Profit YoY | 76.0% | 25.7% |
| EPS (diluted) | $1.52 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.5M | $23.0M | ||
| Q3 25 | $12.2M | $13.8M | ||
| Q2 25 | $12.1M | $14.2M | ||
| Q1 25 | $11.6M | $16.6M | ||
| Q4 24 | $10.1M | $12.9M | ||
| Q3 24 | $10.2M | $9.1M | ||
| Q2 24 | $9.4M | $7.0M | ||
| Q1 24 | $8.4M | $28.9M |
| Q4 25 | $-8.7M | $-95.8M | ||
| Q3 25 | $-26.4M | $-101.3M | ||
| Q2 25 | $-21.6M | $-101.3M | ||
| Q1 25 | $-37.7M | $-114.3M | ||
| Q4 24 | $-36.3M | $-128.9M | ||
| Q3 24 | $-34.3M | $-135.7M | ||
| Q2 24 | $-25.3M | $-147.0M | ||
| Q1 24 | $-24.1M | $-107.4M |
| Q4 25 | 12.2% | — | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | 12.2% | — | ||
| Q1 25 | 12.6% | — | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 13.8% | — | ||
| Q2 24 | 14.3% | — | ||
| Q1 24 | 9.4% | — |
| Q4 25 | -106.1% | -428.9% | ||
| Q3 25 | -149.4% | -808.9% | ||
| Q2 25 | -127.7% | -772.2% | ||
| Q1 25 | -135.6% | -726.6% | ||
| Q4 24 | -166.6% | -1059.9% | ||
| Q3 24 | -176.0% | -1589.0% | ||
| Q2 24 | -146.8% | -1998.6% | ||
| Q1 24 | -122.9% | -394.0% |
| Q4 25 | -69.8% | -416.2% | ||
| Q3 25 | -216.6% | -735.2% | ||
| Q2 25 | -178.3% | -710.8% | ||
| Q1 25 | -324.6% | -687.6% | ||
| Q4 24 | -360.1% | -1001.2% | ||
| Q3 24 | -335.2% | -1489.5% | ||
| Q2 24 | -267.6% | -2112.6% | ||
| Q1 24 | -286.9% | -371.3% |
| Q4 25 | $1.52 | $-0.81 | ||
| Q3 25 | $-1.18 | $-0.92 | ||
| Q2 25 | $-1.63 | $-0.98 | ||
| Q1 25 | $-4.32 | $-1.10 | ||
| Q4 24 | $-4.24 | $-1.27 | ||
| Q3 24 | $-4.01 | $-1.34 | ||
| Q2 24 | $-3.00 | $-1.52 | ||
| Q1 24 | $-2.89 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.2M | $449.9M |
| Total DebtLower is stronger | $483.1M | — |
| Stockholders' EquityBook value | $-166.2M | $671.4M |
| Total Assets | $410.5M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.2M | $449.9M | ||
| Q3 25 | $6.2M | $511.0M | ||
| Q2 25 | $5.3M | $459.7M | ||
| Q1 25 | $18.0M | $503.7M | ||
| Q4 24 | $937.0K | $601.5M | ||
| Q3 24 | $317.0K | $658.1M | ||
| Q2 24 | $9.7M | $691.1M | ||
| Q1 24 | $8.2M | $791.3M |
| Q4 25 | $483.1M | — | ||
| Q3 25 | $484.9M | — | ||
| Q2 25 | $478.3M | — | ||
| Q1 25 | $480.0M | — | ||
| Q4 24 | $436.8M | — | ||
| Q3 24 | $398.4M | — | ||
| Q2 24 | $374.0M | — | ||
| Q1 24 | $329.8M | — |
| Q4 25 | $-166.2M | $671.4M | ||
| Q3 25 | $-158.1M | $748.4M | ||
| Q2 25 | $-132.7M | $715.3M | ||
| Q1 25 | $-134.5M | $779.9M | ||
| Q4 24 | $-100.5M | $872.0M | ||
| Q3 24 | $-65.6M | $962.6M | ||
| Q2 24 | $-32.8M | $971.1M | ||
| Q1 24 | $-9.4M | $1.0B |
| Q4 25 | $410.5M | $842.1M | ||
| Q3 25 | $417.8M | $925.3M | ||
| Q2 25 | $426.8M | $898.9M | ||
| Q1 25 | $447.2M | $986.2M | ||
| Q4 24 | $428.0M | $1.2B | ||
| Q3 24 | $430.8M | $1.2B | ||
| Q2 24 | $438.1M | $1.2B | ||
| Q1 24 | $413.4M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.1M | $-69.3M |
| Free Cash FlowOCF − Capex | $-3.6M | $-69.4M |
| FCF MarginFCF / Revenue | -29.1% | -301.6% |
| Capex IntensityCapex / Revenue | 3.9% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-42.9M | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.1M | $-69.3M | ||
| Q3 25 | $-8.9M | $-76.9M | ||
| Q2 25 | $-8.7M | $-99.6M | ||
| Q1 25 | $-9.6M | $-148.9M | ||
| Q4 24 | $1.2M | $-85.2M | ||
| Q3 24 | $-17.2M | $-84.8M | ||
| Q2 24 | $-4.0M | $-58.2M | ||
| Q1 24 | $-7.1M | $-120.7M |
| Q4 25 | $-3.6M | $-69.4M | ||
| Q3 25 | $-10.1M | $-76.9M | ||
| Q2 25 | $-14.6M | $-99.9M | ||
| Q1 25 | $-14.5M | $-149.7M | ||
| Q4 24 | $-8.6M | $-86.2M | ||
| Q3 24 | $-30.0M | $-86.1M | ||
| Q2 24 | $-28.8M | $-59.2M | ||
| Q1 24 | $-42.1M | $-123.2M |
| Q4 25 | -29.1% | -301.6% | ||
| Q3 25 | -82.8% | -558.2% | ||
| Q2 25 | -121.0% | -701.0% | ||
| Q1 25 | -125.1% | -900.1% | ||
| Q4 24 | -85.3% | -669.4% | ||
| Q3 24 | -293.1% | -945.2% | ||
| Q2 24 | -305.4% | -850.9% | ||
| Q1 24 | -501.8% | -425.7% |
| Q4 25 | 3.9% | 0.5% | ||
| Q3 25 | 9.7% | 0.2% | ||
| Q2 25 | 48.9% | 1.7% | ||
| Q1 25 | 42.8% | 4.4% | ||
| Q4 24 | 97.6% | 7.6% | ||
| Q3 24 | 125.0% | 14.0% | ||
| Q2 24 | 263.0% | 14.5% | ||
| Q1 24 | 417.3% | 8.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LOCL
Segment breakdown not available.
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
